High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
In the presently planned multicentre Phase III trial the two therapies will be compared:
Patients will be randomized after intensified induction treatment with 4 cycles rituximab,
methotrexate, cytarabine and thiotepa (MATRix) between first-line high-dose chemotherapy
against conventional consolidating therapy with 2 cycles of conventional chemotherapy with
R-DeVIC (rituximab, dexamethasone, etoposide, ifosfamide, carboplatin).
Phase:
Phase 3
Details
Lead Sponsor:
University Hospital Freiburg
Collaborators:
German Federal Ministry of Education and Research International Extranodal Lymphoma Study Group (IELSG)